Compare · CODX vs MDLN
CODX vs MDLN
Side-by-side comparison of Co-Diagnostics Inc. (CODX) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CODX and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 8834.6x CODX ($5.4M).
- CODX has been more active in the news (12 items in the past 4 weeks vs 7 for MDLN).
- MDLN has more recent analyst coverage (25 ratings vs 3 for CODX).
- Company
- Co-Diagnostics Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- $5.4M
- $48.08B
- 1M return
- -
- +11.97%
- 1Y return
- -
- -11.77%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2026
- 2025
- News (4w)
- 12
- 7
- Recent ratings
- 3
- 25
Co-Diagnostics Inc.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant and animal genomes. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Latest CODX
- SEC Form 8-K filed by Co-Diagnostics Inc.
- Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection
- Amendment: SEC Form 8-K/A filed by Co-Diagnostics Inc.
- SEC Form 8-K filed by Co-Diagnostics Inc.
- Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
- Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
- Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
- Co-Diagnostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Co-Diagnostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M